ReviewAntibiotics (Basel, Switzerland)2022
Alternatives to Antibiotics against
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- P3MA: A Promising Mycobacteriophage InfectingAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial resistance mechanisms in non-tuberculous mycobacteria.Folia microbiologica · 2025Review
- Clinical Trials involvingThe Ulster medical journal · 2025Article
- Potency of all-D amino acid antimicrobial peptides derived from the bovine rumen microbiome on tuberculous and non-tuberculous mycobacteria.Current research in microbial sciences · 2025Article
- Novel Synthetic Peptide Agelaia-12 Has Improved Activity AgainstPathogens (Basel, Switzerland) · 2024Article
- Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Article
- [Research Trends in Nontuberculous Mycobacterial Treatment].Jugan geon-gang gwa jilbyeong · 2024Review
- Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial Activities.Antibiotics (Basel, Switzerland) · 2024Article
- Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease.Scientific reports · 2024Article
- Article
- Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus.Journal of biomedical science · 2024Article
- Molecular Identification of Strains within thePolish journal of microbiology · 2023Article
- Article
- Exploring Host-Binding Machineries of Mycobacteriophages with AlphaFold2.Journal of virology · 2023Article
- Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.Infectious diseases and therapy · 2023Review
- Updated Review on the Mechanisms of Pathogenicity inMicroorganisms · 2022Review
- Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.BMC infectious diseases · 2022Review
- Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review.Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.